Castle Biosciences Inc Dossier
Qualitative Analysis
Business overview
Castle Biosciences Inc. (Nasdaq: CSTL) is a leading molecular diagnostics company focused on providing personalized, clinically actionable genomic test solutions to improve patient care and disease management. The company primarily serves the dermatologic and gastroenterological fields, offering a robust portfolio of commercially available tests. Key products include DecisionDx-Melanoma (risk stratification for cutaneous melanoma), TissueCypher (an AI-derived spatialomics test predicting progression risk in Barrett's esophagus), DecisionDx-SCC (risk stratification for cutaneous squamous cell carcinoma), MyPath Melanoma (diagnostic aid for difficult melanocytic lesions), and DecisionDx-UM (risk stratification for uveal melanoma). Castle Biosciences operates CAP/CLIA-certified laboratories in Phoenix, Arizona, and Pittsburgh, Pennsylvania, to process its high-complexity molecular tests.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Accelerating the adoption of the TissueCypher Barrett's Esophagus test following guideline inclusion and expanded Medicare coverage, targeting penetration into more than 400,000 annual procedures.
Expected impact: Expected to serve as a key growth driver, with TissueCypher test volume growth approaching approximately 50% year-over-year in 2026.
Collaborating with SciBase to develop a novel test that predicts flare-ups in patients diagnosed with atopic dermatitis (AD) using electrical impedance spectroscopy technology.
Expected impact: Expands Castle's precision dermatology pipeline into inflammatory skin diseases, targeting a massive addressable market.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
To integrate Previse's epigenetic methylation technology (specifically Esopredict) into Castle's gastroenterology franchise, complementing the TissueCypher Barrett's Esophagus test and offering a comprehensive set of testing options for chronic acid reflux-related diseases.
Financial impact: Includes contingent consideration of up to $2.5 million in cash based on the achievement of certain commercial milestones (Earnout Payments).
Strategic Partnerships
Incorporates SciBase's electrical impedance spectroscopy technology into Castle's new diagnostics for skin barrier health and atopic dermatitis, expanding Castle's reach in precision dermatology.
Terms: Castle provided a five-year, SEK 20 million loan to SciBase at an interest rate of STIBOR plus 2% per annum, with the option to convert the loan into new shares of SciBase.